Company news
Atyr Pharma, Inc. (NASDAQ:ATYR) news
Atyr Pharma, Inc. news releases on 6ix. Latest, May 15, 2024: aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American…
Press releases — page 2
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
May 14, 2024
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
May 13, 2024
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
May 1, 2024
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
March 13, 2024
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
February 27, 2024
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
February 20, 2024
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 28, 2024
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
January 17, 2024
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
November 12, 2023
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
November 8, 2023
aTyr Pharma to Present at November Investor Conferences
October 31, 2023
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
October 30, 2023
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
September 10, 2023
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 23, 2023
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
August 8, 2023
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
June 21, 2023
aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
June 19, 2023
aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)
June 5, 2023
aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
May 24, 2023
aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference
May 21, 2023
aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023
aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update
May 8, 2023
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
April 16, 2023
aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases
March 29, 2023
aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
March 20, 2023
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
March 19, 2023
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
March 8, 2023
aTyr Pharma to Present at March Investor Conferences
March 7, 2023
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results
March 1, 2023
aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application
February 28, 2023
aTyr Pharma Announces Pricing of Public Offering of Common Stock
February 8, 2023
aTyr Pharma Announces Commencement of Public Offering of Common Stock
February 7, 2023
aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.
February 5, 2023
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
January 18, 2023
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
January 17, 2023
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
December 14, 2022
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
November 9, 2022
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
November 8, 2022
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
October 10, 2022
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
September 28, 2022
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
September 26, 2022
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
September 12, 2022
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
August 14, 2022
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
August 10, 2022
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
June 13, 2022
aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
May 16, 2022
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
May 15, 2022
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
May 8, 2022
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
April 12, 2022
aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting
April 10, 2022